230 related articles for article (PubMed ID: 28516957)
1. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.
Micol JB; Pastore A; Inoue D; Duployez N; Kim E; Lee SC; Durham BH; Chung YR; Cho H; Zhang XJ; Yoshimi A; Krivtsov A; Koche R; Solary E; Sinha A; Preudhomme C; Abdel-Wahab O
Nat Commun; 2017 May; 8():15429. PubMed ID: 28516957
[TBL] [Abstract][Full Text] [Related]
2. [Frequency and clinical features of ASXL2 gene mutation in acute myeloid leukemia patients with AML1- ETO fusion gene positive].
Zhao JX; Chen XH; Li JL; Pan J; Tan YH; Xu ZF; Ren FG; Zhang YF; Xu J; Li MQ; Li J; Zhang N; Chang JM; Wang XJ; Wang HW
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):676-81. PubMed ID: 27587249
[TBL] [Abstract][Full Text] [Related]
3. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
4. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
[TBL] [Abstract][Full Text] [Related]
6. Loss of Asxl2 leads to myeloid malignancies in mice.
Li J; He F; Zhang P; Chen S; Shi H; Sun Y; Guo Y; Yang H; Man N; Greenblatt S; Li Z; Guo Z; Zhou Y; Wang L; Morey L; Williams S; Chen X; Wang QT; Nimer SD; Yu P; Wang QF; Xu M; Yang FC
Nat Commun; 2017 Jun; 8():15456. PubMed ID: 28593990
[TBL] [Abstract][Full Text] [Related]
7. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
8. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
Nishida S; Hosen N; Shirakata T; Kanato K; Yanagihara M; Nakatsuka S; Hoshida Y; Nakazawa T; Harada Y; Tatsumi N; Tsuboi A; Kawakami M; Oka Y; Oji Y; Aozasa K; Kawase I; Sugiyama H
Blood; 2006 Apr; 107(8):3303-12. PubMed ID: 16380455
[TBL] [Abstract][Full Text] [Related]
9. AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathway.
Zhang Y; Wang J; Wheat J; Chen X; Jin S; Sadrzadeh H; Fathi AT; Peterson RT; Kung AL; Sweetser DA; Yeh JR
Blood; 2013 Jun; 121(24):4906-16. PubMed ID: 23645839
[TBL] [Abstract][Full Text] [Related]
10. [Relation of ASXL2 Gene Mutation with Clinical Characteristics, Prognosis and C-KIT Gene Mutation in AML Patients with AML1- ETO Fusion Gene].
Cui P; Xu D; Xing T; Ren GH; Ma SM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):125-129. PubMed ID: 32027264
[TBL] [Abstract][Full Text] [Related]
11. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal.
Schnoeder TM; Schwarzer A; Jayavelu AK; Hsu CJ; Kirkpatrick J; Döhner K; Perner F; Eifert T; Huber N; Arreba-Tutusaus P; Dolnik A; Assi SA; Nafria M; Jiang L; Dai YT; Chen Z; Chen SJ; Kellaway SG; Ptasinska A; Ng ES; Stanley EG; Elefanty AG; Buschbeck M; Bierhoff H; Brodt S; Matziolis G; Fischer KD; Hochhaus A; Chen CW; Heidenreich O; Mann M; Lane SW; Bullinger L; Ori A; von Eyss B; Bonifer C; Heidel FH
Blood; 2022 Feb; 139(7):1080-1097. PubMed ID: 34695195
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
13. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.
Micol JB; Duployez N; Boissel N; Petit A; Geffroy S; Nibourel O; Lacombe C; Lapillonne H; Etancelin P; Figeac M; Renneville A; Castaigne S; Leverger G; Ifrah N; Dombret H; Preudhomme C; Abdel-Wahab O; Jourdan E
Blood; 2014 Aug; 124(9):1445-9. PubMed ID: 24973361
[TBL] [Abstract][Full Text] [Related]
14. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.
Maiques-Diaz A; Chou FS; Wunderlich M; Gómez-López G; Jacinto FV; Rodriguez-Perales S; Larrayoz MJ; Calasanz MJ; Mulloy JC; Cigudosa JC; Alvarez S
Leukemia; 2012 Jun; 26(6):1329-37. PubMed ID: 22289984
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
[TBL] [Abstract][Full Text] [Related]
16. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
17. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
[TBL] [Abstract][Full Text] [Related]
18. Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia.
Saeed S; Logie C; Francoijs KJ; Frigè G; Romanenghi M; Nielsen FG; Raats L; Shahhoseini M; Huynen M; Altucci L; Minucci S; Martens JH; Stunnenberg HG
Blood; 2012 Oct; 120(15):3058-68. PubMed ID: 22923494
[TBL] [Abstract][Full Text] [Related]
19. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
[TBL] [Abstract][Full Text] [Related]
20. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
